Used as a key intermediate in the synthesis of pharmaceuticals, particularly in the development of bioactive molecules targeting central nervous system disorders. Its structure supports the design of compounds with enhanced metabolic stability and binding affinity due to the presence of the trifluoromethyl group. Commonly employed in medicinal chemistry for optimizing lead compounds in drug discovery programs. Also utilized in the preparation of imidazolidinone-based scaffolds that show potential as enzyme inhibitors or receptor modulators.